Clinical trial

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

NCT05216172

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention AZD1656 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

AZD1656 in Transplantation With Diabetes tO PromoTe Immune TOleraNce

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2019-12-13

PhasePHASE2

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Renal Transplantunresolved

Kidney Transplant; Complicationsunresolved

End Stage Renal Diseaseverified · MONDO: end stage renal failure

Interventions

AZD1656DRUG

PlaceboDRUG

Sponsors & collaborators

Queen Mary University of Londonlead sponsor

AstraZenecacollaborator

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05216172 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.